Corporate Capture of the Rulemaking Process By

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt
Corporate Capture of the Rulemaking Process

By Elizabeth Warren
Jun 14, 2016

(please note: The underlined words are 'clickable' links when accessed via the link at the bottom of this page)

Regulatory capture is a big deal. It is one way in which powerful corporations rig the system to work for themselves—and the rest of America pays the price. The tilt in Congress is pretty much out there for everyone to see, but corporate influence works its magic even better in the shadows—and that’s where rulemaking occurs. This essay focuses on one aspect of this pervasive phenomenon: the capture of agencies as they write the rules.

When it comes to undue industry influence, our rule-making process is broken from start to finish. At every stage, the process is loaded with opportunities for powerful industry groups to tilt the scales in their favor.

The tilt starts early. For example, a 2011 study of U.S. Environmental Protection Agency (EPA) records from 1994 to 2009 found that industry groups held a virtual monopoly over informal communications with EPA that occurred before proposed rules on hazardous air pollutants were publicly available. On average, industry groups engaged in 170 times more informal communications with EPA than public interest players—communications that occurred before any proposed rules were even written.

Similarly, with financial regulation, the big banks and their friends have been lobbying the agencies aggressively. Following the worst financial crisis in three generations—one that resulted in taxpayers spending hundreds of billions to bail out the big banks—Congress passed the Dodd-Frank Wall Street Reform and Consumer Protection Act to ensure that a crisis of that sort never happened again. This law included a provision called the Volcker Rule to stop banks from engaging in certain kinds of risky behavior. But before that rule was even written, groups representing Wall Street interests met with federal regulators 419 times, accounting for over 93 percent of meetings between federal regulators and external parties about the Rule. Less than 7 percent of meetings were with individuals and groups representing the public interest.

As rules wind their way through the process, the lobbying intensifies. When proposed rulemaking notices are published and the public has a formal opportunity to weigh in, their views are quickly buried in an avalanche of detailed, well-funded, well-credentialed comments from industry insiders and their highly-paid allies. Those EPA rules on dangerous air pollutants? Industry groups submitted 81 percent of the comments during the notice-and-comment period. Public interest groups submitted 4 percent.

Some observers argue that this resource mismatch has a smaller impact with agencies than with Congress. Unlike congressional action, agency rules are constrained by well-established judicial review standards that seek to determine whether the agency’s action is supported by the evidentiary record and the authority delegated to it by Congress. Rules must be supported by “substantial evidence”; agency actions must not be “arbitrary and capricious.”

But corporate players are savvy. They have learned that those same judicial review standards can be used to suffocate new rules. They play a sophisticated game—leveraging their own expertise and paying outside experts with purportedly independent credentials to produce long, detailed comments filled with data and analyses, all selectively produced to serve their own interests. This push to bury agencies in detailed, self-serving comments slows the process massively, and their overall dominance of the notice-and-comment process results in rules that are longer, more complicated, and more to the liking of the most powerful players in the game.

Over the last few decades, additional barriers to rulemaking have popped up. Requirements include conducting cost-benefit analyses and evaluating the impact of the rule on small businesses and the environment. Sometimes these processes result in better rules, but often these are just more obstacles that result in even longer, more complex rules, and even more opportunities for well-heeled industry players to slow things down and build in exceptions to benefit themselves.

Consider the Office of Information and Regulatory Affairs, or OIRA, the tiny, obscure, and incredibly powerful agency that reviews significant regulatory proposals developed in other parts of the government before they can take effect. A study of interest group meetings with OIRA showed that between October 1, 2001 to June 1, 2011, OIRA met with five times as many representatives of industry as with people representing public interest groups. And just last year, two professors at the University of Wisconsin-Madison found a strong correlation between interest groups lobbying OIRA and changes in the final rules that favored those interest groups.[1]

These procedures tie agencies in bureaucratic knots and bleed much-needed resources. Often agencies just give up entirely on writing new rules—a situation that tends to play out when Congress or the courts have directed an agency to issue a specific rule by a specific time. A recent study of such deadlines between 1996 and 2014 showed that over 50 percent of final rules were not finished on or before their mandated deadlines. To reiterate, more than half of the time, federal agencies did not meet legally mandated deadlines. For example, Dodd-Frank was passed almost six years ago, but as of today, agencies still have not finalized nearly one quarter of their required rules.

These delays can put lives at risk. Five years ago, Congress passed FDA Food Safety Modernization Act to revamp food safety laws. Regulations were due in 2012. Many were not published until 2015, and then only after a court ordered FDA to publish the regulations. Meanwhile, every year, 3,000 Americans were dying from foodborne illnesses, and 48 million Americans—one in six—was getting sick from contaminated food.

Yet, even if an agency manages to jump through all of the procedural hoops and withstands all the pressure, and actually ultimately issues a final rule, companies will sue. And the rules governing judicial review favor those who would stop the agency from acting in the public interest. Under the law, it is easy for business groups to challenge a rule for being too strong or too restrictive. But it is much harder for public interest groups or ordinary citizens to challenge a rule for being too weak or riddled with loopholes. And it is nearly impossible to challenge successfully an agency for not acting at all.

This certainly takes a toll over time. I talk with agency heads who are like beaten dogs—just trying to keep their heads down. This extreme cautiousness takes an even greater hold over agencies’ general counsels. It is hard to go up against a well-financed machine that will use every tool at its disposal to overturn years of work; it is a lot easier for an agency to give in and write a softer rule—or write no rule at all. Over time, the lobbyists’ work gets done by the agencies’ own lawyers who by this juncture have become so risk averse that they kill off agency action before it even gets off the ground.

To be clear, engaging in informal dialogue, participating in notice-and-comment, and going to court when agencies step out of line are not bad things. But over time, bludgeoning agencies into submission undercuts the public interest. The goal should be to have a system where influence over new rules is measured not by the size of the bankroll, but by the strength of the argument.

Here are a few principles that I believe would balance the scales.

First, increase transparency. The more sunlight that shines on agency processes—and on industry efforts to influence them—the more likely it is that an agency’s final product will reflect the public interest. A good start would be to disclose all meetings between agencies and interested parties, both before and during rulemaking. Another would be to help agencies and courts distinguish between legitimate, high-quality data and research, on the one hand, and bought-and- paid-for studies on the other, by requiring disclosure of financial arrangements and editorial relationships associated with regulatory comments. And anyone who wants to cite their own data should have to publish the dataset online; sure, there need to be safeguards to protect anonymity, for example, but get the data out there where other people can test drive it.

Second, level the playing field between public and private interests. The net effect of a rulemaking process dominated by business advocates is that severely under-resourced public interest advocates are simply out-gunned. States have experimented with systems that build a public advocate into the regulatory process or that compensate public interest advocates who invest resources to produce meaningful feedback on rules. Similarly, judicial review of agencies needs to be reformed to give the public a fighting chance to challenge weak rules, agency inaction, and agency capture.

Third, simplify. Complex rules take longer to finalize, are harder for the public to understand, and inevitably contain more special interest carve-outs that favor big business interests over small businesses and individuals. Complex rules are also more reliant on industry itself to provide additional detail and expertise—and that means more opportunities for capture. Simple works better.

Fourth, limit opportunities for “cultural” capture. Regulators should be beholden to the American people, not to corporate benefactors. Thus, I suggest cracking down on the revolving door, and ending golden parachutes for executives who enter government. In 2013, the Project on Government Oversight released a report showing that major corporations routinely offer their executives financial incentives—to the tune of hundreds of thousands, even millions, of dollars—for accepting government positions. The Financial Services Conflict of Interest Act, a bill introduced by Senator Tammy Baldwin (D-Wis.) and Representative Elijah Cummings (D-Md.), would make these payments illegal under the federal bribery statutes and would target conflicts of interest by removing government employees from decisions that financially benefit their former employers. That is a good start.

Finally, give agencies the money that they need to do their jobs. Writing rules, responding to thousands of comments, and separating valuable data from self-serving nonsense requires capable people with adequate resources. Starving the regulators is the quickest way to ensure that this work is essentially outsourced to the regulated industries themselves.

Regulatory reform is a popular idea, but too many proposals are supported by the industries to be regulated precisely because those proposals would create even more opportunities for them to block regulations that they do not like. Regulatory reform is badly needed, but the reforms must address the central problem—a tilted playing field that benefits the rich and powerful.

Implementing the right kind of reforms will not be easy. The industries that have captured the agencies that are tasked with regulating them will not willingly give up their power and influence. But this is about building a government that works not just for those at the top, but for all of us.

This essay is part of RegBlog’s fifteen-part series, Rooting Out Regulatory Capture.

This essay is based on remarks that Senator Warren delivered at the Regulatory Capture Forum, which the Administrative Conference of the United States convened this spring.

http://www.regblog.org/2016/06/14/warren-corp...g-process/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 135

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 239

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 0

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 158

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 328

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 141

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Senator Whitehouse Addresses Challenges in Climate Summit Attendance

Updated Category News Views 330

Senator Whitehouse's Message on Climate Action Sen. Sheldon Whitehouse emphasized a direct message at this year's U.N. climate summit. He assured global negotiators that the United States remains dedicated to climate action, despite the challenges faced during the Trump administration. Challenges at the U.N. Climate Summit Whitehouse specifically pointed out internal...

Continue Reading
The Surge of Spearmint Oil: Insights on Market Growth to 2033

Updated Category News Views 125

Growing Potential of the Spearmint Oil Market Allied Market Research has revealed exciting projections for the spearmint oil market, anticipating it will escalate from a valuation of $180.1 million in recent years to an impressive $377.5 million by 2033, all the while attaining a compound annual growth rate (CAGR) of 7.7% from 2024 to 2033. Factors Fueling Market...

Continue Reading
Exploring Adobe's Stock Growth Track Record Over Two Decades

Updated Category News Views 212

Adobe Stock: A 20-Year Investment Journey Adobe Inc (NASDAQ: ADBE) has demonstrated exceptional stock performance over the past twenty years, consistently outpacing market averages by 5.02% annually. This remarkable growth culminates in an average annual return of 13.66%, showcasing the strength of Adobe’s business model and innovative contributions to the tech...

Continue Reading
Virginia Housing Program Expands Access with New Limits

Updated Category News Views 187

Virginia Housing Introduces New Income and Sales Price Limits Recently, Virginia Housing announced significant updates regarding the maximum gross household income and sales price limits for homebuyers. This change is destined to benefit numerous first-time and repeat homebuyers across the state of Virginia. With these updates, a wider range of individuals and families...

Continue Reading
DraftKings Poised for Strong Growth in Revenue and Earnings

Updated Category News Views 219

Analysts Optimistic About DraftKings' Future Growth DraftKings Inc (NASDAQ: DKNG) is garnering attention as analysts assess the company's outlook for 2025 following its recent fourth-quarter results. Industry experts are weighing in on the potential for substantial growth in revenue and earnings, indicating a positive trajectory for the company. Strong Analyst Ratings...

Continue Reading